Rare Blood Disorders Product Development Hematology

Provided clinical supervision and management of an expanding hematology clinical trial program (Phase I-III), ensuring patient advocacy within the hospital system and evangelising trials program in greater state health network. Notable clinical trial investigations include Phase 1b zanubrutanib for B-cell non-Hodgkin lymphoma, Phase II isatuximab for multiple myeloma, Phase I blinatumomab for diffuse large B-cell lymphomaDesigned and implemented frontline multidisciplinary workplace education program, emphasising hematology therapeutics and drugs in clinical development/trialLead hematology bedside physician educator for medical, nursing and allied health students, clinical academic appointment via Monash University Delivery of specialist inpatient and ambulatory care to complex hematology and internal medicine patients, within the context of Victoria’s largest private hospital systemSupervised and managed junior medical staff, provided mentorship for academic and clinical performance outcomes. Facilitated remediation and targeted coaching to academically at-risk medical students’ clinical performance

Provided front-line clinical care as internal medicine physician across Australia, in diverse settings; from public metropolitan hospitals experiencing staff shortage, to private hospitals requiring specialist internist cover, to regional and remote hospitals requiring short-term staffing to continue viable operations. Communicated across all levels of healthcare management and front-line staff, proactively identified at-risk clinical scenarios within contracted sites to prevent adverse events. Led teams in a multiple healthcare settings, including prioritising and delegating workflow, identifying growth areas for staff under supervision and encouraging success amongst direct report junior medical and nursing staff Recognised as physician brand ambassador for the Agency, assisted in securing ongoing business contracts for supply of medical staffing solutions. Continually demonstrated ability to perform and enhance cross-functional team performance in novel healthcare settings, improved Agency branding and market penetration through delivery of excellent service to both patients and healthcare organisation clients.

Provided specialist hematology medical care in a complex tertiary academic hospital setting.Responsible for clinical supervision, teaching, mentoring and workflow management of junior staff. Provided regular feedback and coaching plans, including remediation and performance management when required. Gained experience in mature clinical trials program (Phases I-III), including clinical management, safety monitoring/reporting, meticulous documentation management, patient enrollment/recruitment, and ensuring organisational compliance with international trial protocols Notable trials include Phase I mosentuzumab for B-cell non-Hodgkin lymphoma, emicizumab for bleeding prophylaxis in Hemophilia A (HAVEN1), Phase Ib venetoclax in older/refractory acute myeloid leukemia (CAVEAT), Phase III venetoclax/LDAC in intensive chemotherapy ineligible patients (CAVEAT), Phase IIb blinatumomab with cytarabine and methotrexate in adult B-ALL (BLAM), Phase II daratumumab in transplant ineligible multiple myeloma. Facilitated both bedside and formal academic teaching, in clinical hematology, internal medicine exam preparation, laboratory hematology both internally and externally via associated organisations. Attended duties and continuing professional development within the hospital diagnostic and laboratory hematology department, companion biomarker studies for identifying cell surface marker profiles in the choice of minimal residual disease targeting agents for B-ALL. Facilitated ambulatory care Alteplase clinical practice study, teaching best-practice long-term intravenous catheter care in certifying nursing and nurse practitioner staff to utilise line thrombolysis. Authored alteplase institutional protocol adopted across a state-wide network, optimising patient outcomes and reducing financial burden. Audited cost associated with transfusion wastage and implemented strategies to combat inappropriate clinical use of blood productsDrugs and Therapeutics Committee Liaison